Stopped: This particular part of the study could not be completed as endoscopy reports post completion of erlotinib trial were distributed across community and other hos
This study reviews post study clinical endoscopy reports in follow up to patients who participated in MAY2016-07-01 with weekly erlotinib for familial adenomatous polyposis. Reviewing follow up medical records may help researchers examine the extent of rapid progression of familiar adenomatous polyposis disease burden after discontinuation of weekly erlotinib.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of study participants exhibiting clinically significant progression of duodenal neoplasia after completion of study drug
Timeframe: At completion of study
Number of participants who underwent surgical resection
Timeframe: At completion of study
Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms
Timeframe: At completion of study